The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial
University of Edinburgh · Dalhousie University
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
1,188
total citations
- FWCI
- 94.75
- Percentile
- 100%
- References
- 62
Citations per year
Authors
22- PSPeter Sandercock
- PSPeter Sandercock
- JMJoanna M. Wardlaw
- RIRichard I. Lindley
- MDMartin Dennis
Topics & keywords
Topics
Keywords
- Thrombolysis
- Ischaemic stroke
- Medicine
- Recombinant tissue plasminogen activator
- Stroke (engine)
- Randomized controlled trial
- Tissue plasminogen activator
- Acute stroke
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.
Funding
- NINational Institute for Social Care and Health Research
- NINational Institute for Health and Care Research
- SFScottish Funding Council
- SAStroke Association
- UOUniversity of Edinburgh
- NRNational Research Foundation
- DUDalhousie University
- KIKarolinska Institutet
- SLStockholms Läns Landsting
- SHSchweizerische Herzstiftung
- NFNorges Forskningsråd
- CHChest Heart and Stroke Scotland
- MRMedical Research CouncilAwards: MC_G1002455, G0400069, EME 09-800-15, G0400069 and EME 09-800-15
- NHNational Health and Medical Research Council